Andreas Calatzis

Scytl Secure Electronic Voting SA provides electronic and online voting, election management and election modernization solutions. It offers election training, online voter registration, candidate management, electronic ballot delivery and results consolidation. The company was founded by Jorba Andreu Riera and Carles Rovira in 2001 and is headquartered in Barcelona, Spain.

Riva y García Gestión SGIIC SA (Riva y Garcia Private Equity) is a private equity and venture capital subsidiary of Grupo Financiero Riva y García SL /New/ founded in 2000 by Borja García-Nieto Portabella. It is headquartered in Barcelona, Spain.

WeCare-U Comunicación SL is a holding company engages in the publication and distribution of journals, periodicals, digital editions on news, and developments in the health sector. It also provides corporate communications and public relations services to clients in the healthcare industry. Its also provides services such as consulting, content design, printing, television program production, event organization, and workshop facilitation. The company was founded on September 7, 1999 and is headquartered in Madrid, Spain.

Caixa Capital Risc SGEIC SA (Caixa Capital Risc) is a venture capital armof Criteria Caixa SA founded in 2002. The firm is headquartered in Barcelona, Spain with additional offices in Madrid.

Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain.

Haemonetics SA designs, manufactures, markets and services blood processing systems. The company is headquartered in Signy, Switzerland.

Part of Haemonetics Corp., Haemonetics GmbH is a German company that wholesales medical, orthopaedic, dental and laboratory equipment. The company is based in Munich, Germany. The CEOs are Alessandro Casanova, William Patrick Burke. The company was founded in 1981.

Medlumics SL provides medical imaging diagnostics services. It specializes in optically guided medical devices. The firm’s proprietary integrated optics platform technology combines optical and electrical components in a miniature chip, enabling for the first time complex multi view optical probes of the size of a grain of rice and ultra-portable, hand-held OCT systems that produces real-time images. The company was founded by Eduardo Margallo Balbás and Jose Luis Rubio Guivernau on April 3, 2009 and is headquartered in Tres Cantos, Spain.

Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain.

Aelix Therapeutics SL researches and develops therapies for HIV. It develops therapeutic vaccines and immunotherapies to treat HIV infection. The firm is a spin-off of HIVACAT, the Catalan project for the development of effective vaccines against HIV. The company was founded by Christian Brander, Bonaventura Clotet, Josep Maria Gatell and Jordi Naval is headquartered in Barcelona, Spain.

Iproteos SL engages in research and development for schizophrenia treatment. It specializes in the research and development of third-generation drugs for human diseases. The company was founded by Ernest Giralt and Teresa Tarragó and is headquartered in Barcelona, Spain.

Inlog Holdings France SASU develops and sells blood bank and hospital software solutions. The company was founded on July 9, 2008 and is headquartered in Limonest, France.

Part of Haemonetics Corp., Haemonetics Ltd. is a British medical technology company founded in 1975. Haemonetics is based in London, UK. The company provides innovative solutions to improve the quality, effectiveness, and efficiency of medical care. The company's focus is on making a positive impact on patients' lives every day.

AptaTargets SL is a biopharmaceutical company based in Madrid, Spain that focuses on developing therapeutic applications based on aptamer technology. The Spanish company is currently developing aptoll, an immune modulator that blocks the activation of tlr4 in a stroke, representing a novel approach to treat ischemic stroke in the acute phase. It could also be administered in patients up to 48 hours after the stroke. AptaTargets targets indications where inflammation causes significant damage through clinical studies and successful preclinical development. The company was founded in 2014 by David Segarra and María Eugenia Zarabozo, with David Segarra serving as the CEO since then.

SpliceBio SL is a genetic medicines company based in Barcelona, Spain. The Spanish company harnesses its proprietary protein splicing platform to develop the next generation of gene therapies. SpliceBio's platform offers the potential to address diseases that currently cannot be treated with gene therapies because the necessary gene is too large to be delivered by -associated virus (AAV) vectors. The company's lead program targets Stargardt disease, a genetic eye disease that causes vision loss in children and adults. SpliceBio's platform is based on technology developed in the Muir lab at Princeton University after more than 20 years of pioneering intein and protein engineering research. The company was founded by Dominguez Silvia Frutos, Miquel Vila-Perelló, and Miquel Vila-Perelló has been the CEO since incorporation.

Invivo Capital Partners SGEIC SA (Invivo Capital Partners) is a venture capital firm founded in 2019 by Albert Ferrer and Luis Pareras. The firm is headquartered in Barcelona, Spain.

Pulmobiotics SL operates as a spin off company. The firm uses its technology to discover and develop novel treatments and vaccines for respiratory diseases. The company was founded by Maria Lluch and Lluis Serrano and is headquartered in Barcelona, Spain.

Gyala Therapeutics SL develops CAR-T therapies for treating hematological malignancies. The company is based in Barcelona, Spain. Claudio Santos has been the CEO of the Spanish company since 2020.

Telum Therapeutics SL is a Spanish biotechnology company that specializes in drug discovery and the use of Innovative Phage Lytic Proteins as antibiotics. The company is based in Noáin, Spain. The company has specific programs to treat serious multidrug-resistant Gram-negative infections caused by Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa. Telum Therapeutics leverages the power of nature through the understanding of biological controls exerted by bacteriophages to balance bacterial ecosystems. The CEO of the company is Roberto Díez-Martínez.